Biohacking i suplementy 2026 - nootropy, adaptogeny, CBD, kolagen, NMN bez hype’u

Biohacking sells the promise of precision: measure, select a product, optimize. However, when checking the sources behind the most frequently cited numbers, it turns out that some of them do not come from the studies they reference. A 2022 meta-analysis of ashwagandha included 12 studies, not seven. The collagen review covered 11 studies involving 805 people, not 19 studies involving 1125. The combination of caffeine with L-theanine was studied in different doses than most guides report, and the most talked-about Mediterranean diet study circulates in Polish texts in a version that the journal retracted. This text compares the most popular ingredients of the supplement stack with what is actually stated in the abstracts: how many people participated, what the dose was, how long the administration lasted, and what quality the evidence has.

KEY INFORMATION
• Ashwagandha: meta-analysis of 12 randomized studies involving 1002 people, with the credibility of evidence rated as low (Akhgarjand, Phytotherapy Research, 2022).
• Collagen: review of 11 studies involving 805 people, hydrolysate 2.5-10 g daily for 8-24 weeks (Choi, Journal of Drugs in Dermatology, 2019).
• NMN u ludzi: jedno 10-tygodniowe badanie u kobiet po menopauzie ze stanem przedcukrzycowym (Yoshino, Science, 2021).
• CBD: the provisional safe dose according to EFSA is about 2 mg per day for a person weighing 70 kg, and safety cannot be established for individuals taking medications.

What is biohacking really in 2026?

Biohacking is self-optimization of health based on measurement, experimentation, and observation of one's own results. However, under one term, there are three practices with completely different levels of evidence, and confusing them is the source of most misunderstandings in this field.

The first is self-measurement: sleep, resting heart rate, heart rate variability, glucose from a sensor. Measurement is not an intervention, so it does not carry pharmacological risk. The risk here is of a different kind and consists of overinterpreting noise: a single weaker result from a nighttime measurement is not information about health, but just one point in a distribution.

The second practice is tailoring diet and supplements to laboratory test results or genetic profiles. Here, the evidence is weaker than the sale of tests suggests, and I will return to it in the section on biomarkers.

The third is experimental interventions, meaning unregistered substances, peptides, high doses, and products purchased outside of controlled circulation. This is an area where there is neither safety data nor oversight, and the responsibility falls entirely on the person doing it.

The practical conclusion from this division is simple. If the foundations do not work, no supplement will replace them, and if they do work, the gain from supplementation will be small. This is not a slogan, but a consequence of orders of magnitude that the numbers show in the next section.

Why do sleep, diet, and exercise come before supplements?

Because there is data for them that no supplement has. In a study comparing sleep deprivation with alcohol, 39 individuals underwent 28 hours without sleep and, separately, sessions with measured doses of alcohol. After 17-19 hours without sleep, the results of some tests were equal to or worse than results with a blood alcohol content of 0.05 percent, and reaction speed dropped by half in some cases (Williamson i Feyer, Occupational and Environmental Medicine, 2000).

Diet has one of the largest intervention studies in this field behind it. It involved 7447 individuals aged 55-80 years, at high cardiovascular risk, assigned to a Mediterranean diet with extra virgin olive oil, a Mediterranean diet with nuts, or a control diet with reduced fat. The risk ratio for a serious cardiovascular event was 0.69 for the olive oil variant and 0.72 for the nut variant (Estruch i wsp., New England Journal of Medicine, 2018).

It's worth knowing why the 2018 version is cited here. The original publication from 2013 was retracted by the journal after deviations from the randomization protocol were detected, and the authors recalculated the results. Polish texts still provide the number of the retracted version.

Strength training has its own data, independent of aerobic activity. A systematic review of 16 prospective studies showed that muscle-strengthening exercises are associated with a 10-17 percent lower risk of death from any cause and cardiovascular diseases, cancers, and diabetes, with the greatest reduction occurring at about 30-60 minutes per week (Momma i wsp., British Journal of Sports Medicine, 2022).

Which nootropics have the strongest evidence?

The best-documented combination is caffeine with L-theanine, but in different doses than most guides suggest. In a placebo-controlled study, 50 mg of caffeine was compared with the same dose of caffeine given together with 100 mg of L-theanine in 27 individuals. The combination improved speed and accuracy in a task switching task and reduced susceptibility to distracting information (Owen i wsp., Nutritional Neuroscience, 2008).

A second study from the same year used higher doses: 150 mg of caffeine and 250 mg of L-theanine, in an alternating design with randomization and placebo. The combination shortened reaction time, improved accuracy in visual information processing tests, and reduced reported mental fatigue (Haskell i wsp., Biological Psychology, 2008).

The same work contains a result that L-theanine marketing does not cite. L-theanine alone, without caffeine, increased reported headaches and worsened performance in subtracting sevens. The effect of this pair comes from the combination, not from the amino acid.

Bacopa monnieri has a meta-analysis, but it measures something different than is usually written. The review included 9 randomized placebo-controlled studies involving 518 individuals, all with a duration of at least 12 weeks, and the analysis covered 437 participants. The improvement concerned attention speed: shortening the time in the Trail B test and reaction time with choice, not memory as such (Kongkeaw i wsp., Journal of Ethnopharmacology, 2014).

Is modafinil a nootropic for healthy individuals?

Modafinil is a prescription medication, not a supplement, and this practically resolves the issue before the discussion about efficacy begins. Purchasing it outside of pharmacy circulation is not a legal purchase, and use outside of indications occurs without oversight, which is significant for a drug with psychostimulant effects.

The cognitive data are less clear-cut than the headlines suggest. A systematic review covered studies on the effects of modafinil in healthy, non-sleep-deprived individuals published from January 1990 to December 2014. The authors found that in simple test paradigms, modafinil improves executive functions, but improvements in attention and learning and memory were shown in only half of the studies (Battleday i Brem, European Neuropsychopharmacology, 2015).

There is also a result that contradicts the picture from forums. Some studies noted a deterioration in divergent creative thinking. Only with more complex tasks did the picture become more coherent and show improvements in attention, executive functions, and learning.

The authors did not find an advantage in adverse effects or mood changes in the reviewed studies, but they themselves emphasize methodological discrepancies throughout this literature and conclude the work with a set of recommendations on how future studies should be conducted. This is a description of an open field, not a confirmed remedy for concentration.

What do studies on lion's mane show?

The most frequently cited study concerns older adults with mild cognitive impairment, not healthy adults. Thirty participants aged 50-80 were randomly assigned to two groups of 15. The active group took four 250 mg tablets containing 96 percent dried lion's mane, three times a day, totaling 3 g per day, for 16 weeks (Mori et al., Phytotherapy Research, 2009).

Results on the cognitive function scale based on the modified Hasegawa scale were significantly higher than in the placebo group at weeks 8, 12, and 16, thus increasing over time of intake. Four weeks after discontinuation, results significantly dropped, suggesting an effect dependent on current administration, not a lasting change.

A newer study included healthy individuals and presented a more modest picture. Forty-one adults aged 18-45 received 1.8 g of lion's mane or placebo. After a single dose, participants performed the Stroop test faster in measurements after 60 minutes, while after 28 days of intake, only a trend towards lower subjective stress was observed, on the verge of significance (Docherty i wsp., Nutrients, 2023).

The authors of this second work themselves call it a pilot study and caution against the results due to the small sample size. They also noted zero results and some adverse results. Thus, the comparison of both studies gives one signal in the clinical population and one cautious acute signal in healthy individuals, but no confirmed improvement in memory.

Does ashwagandha really lower cortisol?

In the most frequently cited study, it decreased, and this number holds up to scrutiny. Sixty-four individuals with chronic stress were randomly assigned to placebo or root extract, taking one 300 mg capsule twice a day for 60 days, totaling 600 mg per day. Serum cortisol decreased in the active group by 27.9 percent compared to 7.9 percent in the placebo group, and the difference was statistically significant (Chandrasekhar i wsp., Indian Journal of Psychological Medicine, 2012).

The full text also contains information worth knowing when choosing a product. A specific commercial extract KSM-66 was studied, provided by the manufacturer, obtained exclusively from the root and standardized for a content of at least 5 percent withanolides using the HPLC method. The result pertains to this standardization, not any random root powder.

A broader picture is given by a meta-analysis from 2022, in which the number of studies is often confused. It included 12 randomized studies with a total of 1002 participants aged 25-48 years. Ashwagandha reduced anxiety and stress levels compared to placebo, and the analysis of dose dependency indicated a beneficial effect for stress at 300-600 mg per day (Akhgarjand i wsp., Phytotherapy Research, 2022).

The authors themselves add two caveats that usually fall out of citations. Heterogeneity between studies was very high, and the certainty of evidence was rated as low for both outcomes. The conclusion is therefore: the effect is visible and repeatable, but the quality of the evidence base requires further high-quality research.

What is known about rhodiola and reishi?

Less than product descriptions suggest, and of lower quality. The most frequently cited study on rhodiola was neither randomized nor blinded. It was a multicenter open-label study with one arm, in which 101 individuals with symptoms of life stress took extract WS 1375 at 200 mg twice a day for four weeks (Edwards i wsp., Phytotherapy Research, 2012).

All the questionnaires used showed improvement, with the first changes noted after just three days. However, a study without a control group does not allow for the separation of the product's effects from the expectations and the natural course of symptoms, and the improvement after three days is more of an argument for the latter than the former.

Reishi has undergone a Cochrane review, and the result is not what appears on labels. The review included five randomized studies involving oncology patients. Those receiving the mushroom alongside chemotherapy or radiotherapy responded to treatment more frequently, but the confidence interval for this result included a lack of effect (Jin i wsp., Cochrane Database of Systematic Reviews, 2016).

The authors' conclusion is clear: there is insufficient evidence to use reishi as a first-line treatment for cancer, and the methodological quality of the primary studies was generally unsatisfactory. For consumer indications, such as sleep and immunity in healthy individuals, this review says nothing, as it did not study them. I compare these three plants more broadly in the post o adaptogenach na stres.

What do studies say about CBD for anxiety and sleep?

The two most frequently cited studies differ in quality enough to warrant separation. The first was a randomized, double-blind study: 24 individuals with untreated social phobia received a single dose of 600 mg of cannabidiol or a placebo before a simulated public speaking test, with a separate group consisting of 12 healthy individuals. Cannabidiol significantly reduced anxiety and discomfort during the presentation (Bergamaschi i wsp., Neuropsychopharmacology, 2011).

The second study was a retrospective review of the records of 103 patients from a psychiatric clinic, of which 72 individuals were included in the analysis: 47 with anxiety as the main issue and 25 with sleep disorders. Anxiety scores decreased in the first month for 79.2 percent of patients and remained at a lower level, while sleep scores improved for 66.7 percent, but fluctuated over time (Shannon et al., The Permanente Journal, 2019).

The authors of this second study state directly that controlled studies are needed. An analysis of records without a comparative group does not separate the action of the substance from concurrent treatment, the natural course of symptoms, or patient expectations.

For practice, this means one distinction. The signal regarding anxiety is real, but it comes from a single dose that is many times higher than what is sold as a daily portion, and from uncontrolled observations. I discuss the combination of CBD with adaptogens separately in the post on the synergy of CBD and adaptogens.

How much CBD is absorbed and what dose is safe?

The answer to the first question is: it is unknown. A systematic review of the pharmacokinetics of cannabidiol in humans gathered 24 studies with pharmacokinetic data and found that absolute bioavailability was measured only after smoking, where it was 31 percent. No study has established it for oral and sublingual routes (Millar et al., Frontiers in Pharmacology, 2018).

This removes from circulation the table repeated in Polish texts about CBD, where the sublingual route supposedly has 13-19 percent, and the oral route 6-15 percent. These values do not come from measurements in humans. However, the review indicates that maximum concentration increases after a meal and in fat formulations, and the time to reach it ranges from 0-4 hours.

The second question is answered by the latest position of the EFSA panel. The provisional safe dose is 0.0275 mg per kilogram of body weight per day, which is about 2 mg daily for a person weighing 70 kg, and was derived using the benchmark dose method with an uncertainty factor of 400 (EFSA, panel NDA, 2026).

This dose applies only to supplements with a purity of cannabidiol of at least 98 percent, without nanoparticles. The panel also states what cannot be established: the safety of CBD cannot be determined in individuals under 25 years of age, in pregnant and breastfeeding women, and in individuals taking medications simultaneously. The circulating statement on the safety of doses up to 1500 mg per day, attributed to a report by the World Health Organization, is not supported by summaries of the studies to which it is sometimes attached. The discrepancy between these two numbers is five hundredfold.

What is really known about CBG?

There is one study describing users, and it is a survey, not a clinical trial. It involved 127 individuals from the USA aged 21 and older who had used cannabis products with a predominance of cannabigerol in the previous six months. The most frequently cited reasons for use were anxiety in 51.2 percent of respondents, chronic pain in 40.9 percent, depression in 33.1 percent, and insomnia in 30.7 percent (Russo i wsp., Cannabis and Cannabinoid Research, 2022).

The declared effectiveness was high. Most participants rated their condition as greatly improved or improved, and 80 percent of those treating depression and 78.3 percent of those treating anxiety reported an advantage over their previous pharmacological treatment. 44 percent of respondents reported no adverse effects, with the most common being dry mouth and drowsiness.

The authors call their work the first survey of patients using products with a predominance of CBG and cautiously conclude: the study shows that people use CBG, and justifies conducting randomized studies. It does not show that CBG works.

It is worth noting what is not present in this work, as Polish texts attribute a role to CBG as a focus-enhancing ingredient. The survey did not measure concentration or attention at all, and the percentage of 51.2 percent refers to anxiety as a reason for use, not improvement in focus. The version about morning CBG for concentration has no source in this work.

Does collagen for the skin really work?

There is evidence, although more modest than what most product descriptions claim. A systematic review of randomized, placebo-controlled studies included 11 works and 805 patients. In eight of them, collagen hydrolysate was used at doses ranging from 2.5 to 10 g daily for 8-24 weeks, in two collagen tripeptide at 3 g daily, and in one dipeptide (Choi i wsp., Journal of Drugs in Dermatology, 2019).

The authors formulate their conclusions as preliminary but consistent: oral collagen supplementation improves skin elasticity and hydration and the density of skin collagen, and no adverse events were reported. They also emphasize the lack of regulations regarding the quality of products and the need to establish an optimal dosing regimen.

The most frequently cited single study involved 114 women aged 45-65 who took 2.5 g of a specific bioactive peptide or a placebo for 8 weeks. The volume of wrinkles around the eyes decreased by 20 percent compared to the placebo group, and biopsies showed a 65 percent higher content of type I procollagen and an 18 percent increase in elastin (Proksch i wsp., Skin Pharmacology and Physiology, 2014).

Two clarifications are needed here, as distorted versions circulate in Polish texts. In this study, there was no arm with a 5 g dose, and the increase in fibrillin content by 6 percent did not reach statistical significance. However, the effect persisted for four weeks after the cessation of intake. You can find more about the types of products in the post on the properties of collagen.

Do NMN and resveratrol slow down aging?

This has not been studied in humans at all, and the existing data pertains to something else. A ten-week randomized, placebo-controlled, double-blind study involved postmenopausal women with prediabetes, overweight, or obesity. Muscle sensitivity to insulin and insulin signaling in muscle increased after NMN, while it did not change after placebo (Yoshino i wsp., Science, 2021).

This is one study, in a narrowly defined group, with a metabolic endpoint, not related to lifespan. The authors reference in the introduction evidence from rodent models: obesity and aging impair the production of nicotinamide adenine dinucleotide, contributing to metabolic disorders. This is the starting hypothesis of the study, not proof of the product's action in healthy humans.

Resveratrol has more data in humans and performs worse than its reputation suggests. A meta-analysis of 11 randomized studies involving 388 individuals showed significant reductions in fasting glucose, insulin, hemoglobin A1c, and insulin resistance index, but only in individuals with diabetes. No significant effect on glycemic parameters was found in individuals without diabetes (Liu i wsp., The American Journal of Clinical Nutrition, 2014).

This finding reverses the typical sales narrative. If you are healthy and take resveratrol preventively, you are exactly in that group where the meta-analysis found no effect. I discuss this ingredient separately in the post on the properties of resveratrol.

How to recognize a supplement driven by marketing?

Five questions are enough to sift through most products, and all can be asked in a few minutes. First: are there studies on humans, not just on animals or in cell cultures? Second: did the study have a placebo group and randomization, because without them, improvement describes the course of symptoms, not the effect of the preparation.

The third question concerns numbers. How many people participated and how many completed the study? In trials involving dozens of people, a single result does not clarify anything, and the authors of such studies usually state this themselves, as seen in the cited studies on lion's mane and NMN.

The fourth question concerns time and the endpoint. A supplement studied for four weeks tells us nothing about the effects of a year of use, and an improvement in a blood marker is not the same as fewer heart attacks or a longer life. Fifth: does the manufacturer provide a certificate of analysis for the batch, showing the actual content of the active substance and the absence of heavy metals and pesticides?

Additionally, there is one reflex that saves the most time. Check the citations before you believe them: paste the PMID or PMC number into the PubMed search engine and read the title that opens. In organizing this text, 15 out of 29 identifiers listed as sources led to works from other fields, including an article on orthostatic tremor and a study on zinc-binding protein. All had the correct format and all opened without error.

What are the real risks of combining supplements?

The greatest risk does not lie in a single preparation, but in their number. A review concerning people over 65 years old states that nearly half of them take at least one medication that is not medically necessary, and the relationship between polypharmacy and adverse clinical outcomes is well documented (Maher i wsp., Expert Opinion on Drug Safety, 2014).

For cannabidiol, the risk of interactions is specifically described. A review based on the characteristics of registered CBD products states that adverse effects occurred in nearly half of users, with a clear dose-dependent relationship, and the most common of these were increased aminotransferase activity, drowsiness, sleep disturbances, infections, and anemia (Brown and Winterstein, Journal of Clinical Medicine, 2019).

The mechanism of these interactions is known. Cannabidiol interacts with the isoenzymes CYP3A4 and CYP2C19 as well as with P-glycoprotein, which are pathways responsible for the metabolism and excretion of many commonly used medications. The authors recommend considering reducing the doses of substrates, monitoring adverse effects, or choosing alternative therapies, especially in patients burdened with multiple diseases.

Additionally, there is the regulator's position mentioned above. Since the safety of CBD cannot be established in individuals taking medications, discussing it with the attending physician before adding it to the regimen is not a formality, but the only available way to assess risk. The same principle applies to pregnant and breastfeeding women and individuals under 25 years of age.

Why measure biomarkers before supplementation?

To know what is lacking instead of guessing. An analysis of a representative population study in the United States included 4,495 adults and showed a deficiency of vitamin D, defined as a concentration of 25-hydroxyvitamin D equal to 20 ng per milliliter or lower, in 41.6 percent of the respondents (Forrest i Stuhldreher, Nutrition Research, 2011).

The set from which such an assessment usually begins includes a complete blood count with a smear, lipid profile, fasting glucose with glycated hemoglobin, TSH, and 25-hydroxyvitamin D. However, the range of tests and frequency is determined by the physician, as they depend on age, symptoms, and accompanying diseases. The point is clear: to distinguish actual deficiency from presumed deficiency before purchasing a preparation.

The situation is different for genetic tests, marketed as a tool for diet personalization. A European randomized study included adults from seven countries, of which 1,269 completed the intervention, comparing standard advice with personalized advice on three levels: based on diet alone, diet with phenotype, and diet with phenotype and genotype (Celis-Morales i wsp., International Journal of Epidemiology, 2017).

The result is unequivocal and contrary to the sales promise. Personalized advice performed better than standard advice, but there was no evidence that adding phenotypic or genotypic information improved its effectiveness. The effect was achieved by matching the actual diet of the participant, not their genetic variants.

Summary: what remains after checking the sources

After compiling all citations with their sources, the picture is narrower but stronger. The best-documented foundations remain: sleep, a Mediterranean-pattern diet, and regular exercise, including strength training. For these, there are studies on thousands of people with hard endpoints, while for no supplement in this text are such data available.

In the realm of supplementation, the most consistent signal comes from three things. Caffeine with L-theanine in attention tasks, ashwagandha in stress reduction, with low certainty of evidence, and collagen peptides in skin parameters. The rest is either promising and poorly researched, like bacopa and lion's mane, or studied and disappointing, like resveratrol in non-diabetic individuals.

Separately stands the conclusion that cannot be derived from any single study. Supplement marketing regularly inflates the number of studies, shifts doses, and distorts the direction of results, doing so consistently enough that checking citations is now part of reading the label. The three most common misrepresentations in this text concerned the number of studies in the meta-analysis, the dose used in the study, and the group in which the effect occurred.

The practical conclusion is small and therefore credible. Three preparations for a specific, measured deficiency will suffice for most people, and each additional one should have a named study and a named goal. The assortment is gathered in the category supplements, check the certificate of analysis for the specific product, and leave the decision to combine preparations with medications to the doctor.

Frequently Asked Questions

Is biohacking pseudoscience?

Not entirely, but the weight of evidence is very unevenly distributed. Sleep, diet, and exercise have studies involving thousands of people. Some supplements have single small studies, while others are based solely on animal models. The problem is not the practice itself, but treating these three levels as equivalent.

Which nootropic has the best evidence?

Combination of caffeine with L-theanine. In a placebo-controlled study of 27 individuals, it improved the speed and accuracy of attention switching with 50 mg of caffeine and 100 mg of L-theanine (Owen i wsp., Nutritional Neuroscience, 2008). A second study used 150 mg of caffeine and 250 mg of L-theanine and obtained similar directional results.

Does ashwagandha lower cortisol?

In a study of 64 individuals with chronic stress, serum cortisol decreased by 27.9 percent after 60 days of taking 300 mg twice daily, compared to 7.9 percent in the placebo group (Chandrasekhar i wsp., Indian Journal of Psychological Medicine, 2012). A meta-analysis of 12 studies confirms stress reduction but rates the certainty of evidence as low.

Does collagen work for wrinkles?

In a study of 114 women aged 45-65, taking 2.5 g of bioactive peptide for 8 weeks reduced the volume of wrinkles around the eyes by 20 percent compared to placebo (Proksch i wsp., Skin Pharmacology and Physiology, 2014). A review of 11 studies involving 805 individuals confirms improvements in skin elasticity and hydration.

Does resveratrol provide benefits for healthy individuals?

A meta-analysis of 11 randomized studies involving 388 individuals showed an improvement in glycemic control only in individuals with diabetes. No significant effect was found on any of the studied parameters in non-diabetic individuals (Liu i wsp., The American Journal of Clinical Nutrition, 2014).

How many supplements can be safely combined?

There is no number designated by the study. However, it is known that polypharmacy is associated with adverse clinical outcomes, and nearly half of individuals over 65 take at least one preparation that is not necessary (Maher i wsp., Expert Opinion on Drug Safety, 2014). Keep a list and show it to your doctor.

Do genetic tests help tailor diet?

In a European randomized study involving 1269 participants, personalized advice performed better than standard advice, but adding genotypic information did not improve its effectiveness (Celis-Morales i wsp., International Journal of Epidemiology, 2017). The effect was due to matching the actual diet, not genetic variants.

What dose of CBD is considered safe?

The EFSA panel derived a provisional safe dose of 0.0275 mg per kilogram of body weight per day, which is about 2 mg per day for a person weighing 70 kg (EFSA, 2026). Safety cannot be established for individuals under 25 years of age, pregnant women, nursing mothers, and those taking medications.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use hemp or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Opublikowano: 2026-05-11 · Aktualizacja: 2026-08-10